3/12/2023 0 Comments Cracker barrel eagleHowever, generic competition for several drugs and rising competitive pressure, mainly on the diabetes franchise, will continue to be overhangs on the top line. Its new COVID oral antiviral pill, Lagevrio has become a key top-line driver in 2022. With continued label expansion into new indications & early-stage settings, Keytruda is expected to remain a key top-line driver.Īnimal health and vaccine products are core growth drivers. The company’s drugs like Keytruda, Gardasil vaccine and Bridion have been driving sales. Merck’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+20.0% vs. You can see all of today’s research reports here > These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. (MRK), ConocoPhillips (COP) and Adobe Inc. Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. The Zacks Research Daily presents the best research output of our analyst team.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |